How do you give patients a voice in the complex world of pharma and drug development? It's one of the central questions facing the biopharmaceutical industry in the era of value-based care, and the primary question that drives the dialogue at the annual BIO Patient and Health Advocacy Summit.
This year's summit, which took place in late October in Washington, DC, brought patient advocacy organizations, academic leaders, regulators, biotechnology industry leaders and other stakeholders together to discuss better ways to advocate for patient needs and make sure recipients of care have access to affordable and effective medicines. The summit, organized by the Biotechnology Innovation Organization (BIO), is one of the prime opportunities that experts in this space have to share best practices and new ideas. And this year, there was no shortage of useful insights.
Here are three key takeaways from the event.